Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of a 9-valent HPV vaccine (E. coli–derived) in Chinese women
CTR20190658Phase 2Completed
- Sponsor
- Wantai BioPharm
- Start
- May 2019
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of human papillomavirus 9-valent vaccine, recombinant in human papillomavirus infection, anogenital warts, Cervical Cancer (CC), sponsored by Wantai BioPharm. Started May 2019; status: completed.
02
Drugs
human papillomavirus 9-valent vaccine, recombinant
03
Conditions
human papillomavirus infectionanogenital wartsCervical Cancer (CC)
Beyond the preview
Go deeper on CTR20190658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190658.